HomeEBS • NYSE
Emergent Biosolutions Inc
add
$4.66
5.28%
After Hours:(0.86%)-0.040
$4.62
Closed: Mar 28, 5:56:03 PM UTC-4 · USD · NYSE · Disclaimer
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 194.70M | -29.61% |
Operating expense | 140.80M | -33.40% |
Net income | -31.30M | 36.77% |
Net profit margin | -16.08 | 10.17% |
Earnings per share | 0.05 | 106.49% |
EBITDA | 21.00M | 255.56% |
Effective tax rate | -13.41% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 99.50M | -10.92% |
Total assets | 1.39B | -23.78% |
Total liabilities | 906.90M | -22.74% |
Total equity | 482.80M | — |
Shares outstanding | 54.34M | — |
Price to book | 0.55 | — |
Return on assets | -0.75% | — |
Return on capital | -0.92% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -31.30M | 36.77% |
Cash from operations | -79.90M | -348.91% |
Cash from investing | 28.60M | 350.88% |
Cash from financing | 500.00K | -89.36% |
Net change in cash | -50.80M | -312.55% |
Free cash flow | -5.54M | -113.72% |
Previous close
$4.92
Day range
$4.53 - $4.94
Year range
$1.82 - $15.10
Market cap
253.21M USD
Avg Volume
1.37M
P/E ratio
-
Dividend yield
-
Primary exchange
NYSE
About
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Founded
Sep 5, 1998
Headquarters
Website
Employees
900
